26.6.2025 14:24:32 CEST | Thor Medical ASA | Total number of voting rights and
capital
Oslo, Norway, 26 June 2025: Reference is made to stock exchange announcement by
Thor Medical ASA (the "Company") on 18 June 2025 regarding the successful
completion of a private placement of a total of 30,000,000 new shares in the
Company raising a total of NOK 75 million in gross proceeds (the "Private
Placement") and a retail offering of a total of 4,577,399 new shares raising a
total of approx. NOK 11.4 million in gross proceeds (the "PrimaryBid Offering").
The share capital increase relating to the Private Placement and the share
capital increase relating to the PrimaryBid Offering is now registered with the
Norwegian Register of Business Enterprises. The Company's share capital is after
the registration NOK 69,797,184 divided into 348,985,920 shares. Each share has
a nominal value of NOK 0.20 and represents one vote in the Company's general
meeting.
DISCLOSURE REGULATION
This information is required to be disclosed under Section 5-12 of the
Securities Trading Act.
CONTACTS
Brede Ellingsæter, CFO & COO, Thor Medical ASA, +47 472 38 440,
brede.ellingseter@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.
ATTACHMENTS
Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18581837/6253/Download%20announce
ment%20as%20PDF.pdf